BioRestorative Therapies, Inc. (NASDAQ:BRTX) Major Shareholder Dale Broadrick Acquires 86,041 Shares of Stock

BioRestorative Therapies, Inc. (NASDAQ:BRTXGet Free Report) major shareholder Dale Broadrick bought 86,041 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The stock was purchased at an average price of $1.32 per share, for a total transaction of $113,574.12. Following the completion of the acquisition, the insider now owns 477,972 shares in the company, valued at $630,923.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Dale Broadrick also recently made the following trade(s):

  • On Wednesday, February 7th, Dale Broadrick bought 36,374 shares of BioRestorative Therapies stock. The stock was purchased at an average price of $1.38 per share, for a total transaction of $50,196.12.
  • On Friday, December 1st, Dale Broadrick sold 250 shares of BioRestorative Therapies stock. The stock was sold at an average price of $1.88, for a total value of $470.00.
  • On Monday, November 27th, Dale Broadrick sold 278 shares of BioRestorative Therapies stock. The stock was sold at an average price of $1.89, for a total value of $525.42.

BioRestorative Therapies Stock Up 7.4 %

NASDAQ BRTX opened at $1.45 on Tuesday. The company has a fifty day moving average of $1.76. BioRestorative Therapies, Inc. has a 12 month low of $1.20 and a 12 month high of $7.13.

BioRestorative Therapies (NASDAQ:BRTXGet Free Report) last released its quarterly earnings results on Monday, November 13th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.04. The business had revenue of $0.03 million during the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative return on equity of 117.00% and a negative net margin of 12,195.10%. Equities analysts expect that BioRestorative Therapies, Inc. will post -3.52 EPS for the current year.

Institutional Investors Weigh In On BioRestorative Therapies

A number of institutional investors and hedge funds have recently bought and sold shares of BRTX. Vanguard Group Inc. increased its position in shares of BioRestorative Therapies by 8.6% during the 3rd quarter. Vanguard Group Inc. now owns 137,818 shares of the company’s stock valued at $247,000 after purchasing an additional 10,862 shares during the last quarter. Lynwood Capital Management Inc. bought a new position in shares of BioRestorative Therapies during the 3rd quarter worth $36,000. Finally, FNY Investment Advisers LLC bought a new position in shares of BioRestorative Therapies during the 3rd quarter worth $26,000. 6.93% of the stock is owned by hedge funds and other institutional investors.

BioRestorative Therapies Company Profile

(Get Free Report)

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.

Featured Articles

Insider Buying and Selling by Quarter for BioRestorative Therapies (NASDAQ:BRTX)

Receive News & Ratings for BioRestorative Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioRestorative Therapies and related companies with MarketBeat.com's FREE daily email newsletter.